Retatrutide Phase 3: 32% weight loss vs tirzepatide's 21%
Retatrutide is Eli Lilly's next-generation incretin: a triple agonist of GLP-1, GIP, and glucagon receptors. Phase 2 data showed mean weight loss of ~24% at 48 weeks on the top dose; ongoing Phase 3 trials look likely to extend that toward 30%+ in some cohorts.
What glucagon adds
Glucagon is typically thought of as the "raise blood sugar" hormone — opposed to insulin. That's true in acute settings. Chronically, glucagon receptor activation in the liver and adipose tissue does something else:
- Increases hepatic energy expenditure. The liver burns more fatty acids when glucagon signaling is elevated.
- Reduces hepatic fat content. Significant for MASLD/MASH outcomes.
- Mobilizes adipose stores. Increases lipolysis at the fat cell.
- Modestly raises basal metabolic rate. ~3–5% increase observed in trial.
Combined with GLP-1's appetite suppression and GIP's insulin-sensitizing/anti-nausea effects, glucagon agonism adds an "increase output" arm to the "decrease input" arms of the existing drugs. The net is bigger weight loss for the same level of appetite suppression.
The trial data
| Trial / Drug | Dose | Duration | Mean weight loss |
|---|---|---|---|
| Retatrutide Phase 2 | 12 mg weekly | 48 weeks | ~24.2% |
| Retatrutide Phase 2 | 8 mg weekly | 48 weeks | ~21.7% |
| Tirzepatide (SURMOUNT-1) | 15 mg weekly | 72 weeks | ~20.9% |
| Semaglutide (STEP-1) | 2.4 mg weekly | 68 weeks | ~14.9% |
| Retatrutide Phase 3 (TRIUMPH, ongoing) | 12 mg weekly | 76 weeks (projected) | ~24–30% (projected) |
The headline 32% comes from a high-responder subgroup in Phase 2 — roughly the top quartile of patients on 12 mg. The mean is ~24%. Phase 3 will refine the median and tails.
The side-effect picture
Glucagon agonism comes with its own profile: transient elevations in fasting glucose (paradoxically, balanced by the GLP-1/GIP arms) and increases in heart rate of ~5–7 bpm sustained. The GI profile is similar to tirzepatide — nausea, vomiting, constipation, but no obvious worsening.
Two specific monitoring points:
- Heart rate. A persistent +7 bpm shift in resting heart rate is small but worth tracking, especially in patients with pre-existing arrhythmia or coronary disease.
- Hepatic enzymes. Glucagon increases fatty-acid flux through the liver. Trials saw transient ALT/AST elevations that resolved with continued therapy.
When it might arrive
Lilly's TRIUMPH program is the Phase 3 stage. Primary completion estimates target 2026–2027 for the obesity indication, with potential approval and launch in 2027–2028. T2D, MASH, and OSA indications are also in development.
What this means for current GLP-1 users
- Don't wait if you have an active need. Tirzepatide is a strong drug with broad availability. The marginal gain from retatrutide is real but two years out.
- The switch will not be free. Different titration schedule, different dose increments. Expect a 4–6 month re-titration window if you switch.
- Heart-rate monitoring matters more. If you have cardiovascular comorbidity, retatrutide's +7 bpm is worth a conversation with your cardiologist before switching.
FAQ
Is retatrutide available now?
Only in clinical trials. Compounded "retatrutide" sold by online vendors is not Lilly's drug — it's research-use-only peptide of unverifiable identity and quality.
Will retatrutide cause hyperglycemia from the glucagon arm?
In trials, no — the GLP-1 and GIP arms more than offset the glucagon effect on fasting glucose. T2D patients on retatrutide saw HbA1c reductions similar to tirzepatide.
Should I switch from tirzepatide to retatrutide at launch?
For most people, only if you've plateaued on tirzepatide at a dose you tolerate. Switching means re-titration and a 4–6 month return to a maintenance dose; not free.
What's the structural difference between retatrutide and tirzepatide?
Retatrutide is a single peptide engineered to bind all three receptors. Tirzepatide is engineered to bind GLP-1 and GIP. Both are once-weekly synthetic peptides.
Related reading
Watch the pipeline
Peptide Protocol updates investigational drug profiles as trials publish, so you know which next-generation therapy is closest to your goal.
Get the iPhone app →Informational and educational only. Not medical advice. Consult a licensed clinician before starting, changing, or stopping any peptide protocol. Mentions of investigational, compounded, or research-use peptides are for informational purposes; many such substances are not FDA-approved for human use.